Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program
Bachireddy C, Shrestha R, Bromberg DJ, Azbel L, Kurmanalieva A, Wegman M, Shumskaya N, Rozanova J, Meyer JP, Altice FL. Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal Of Drug Policy 2021, 101: 103558. PMID: 34915426, PMCID: PMC9998103, DOI: 10.1016/j.drugpo.2021.103558.Peer-Reviewed Original ResearchConceptsHIV statusMean treatment durationOpioid use disorderPositive HIV statusDuration of treatmentMethadone doseHIV incidenceMethadone servicesMethadone treatmentIndependent correlatesHIV preventionUse disordersTreatment durationMethadoneNational programTreatmentHIVAdministrative dataCommunity releaseMonthsKyrgyz prisonsFirst evaluationIncarcerated peopleDurationReleasePvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon
Villasis E, Garro K, Rosas-Aguirre A, Rodriguez P, Rosado J, Gave A, Guzman-Guzman M, Manrique P, White M, Speybroeck N, Vinetz JM, Torres K, Gamboa D. PvMSP8 as a Novel Plasmodium vivax Malaria Sero-Marker for the Peruvian Amazon. Pathogens 2021, 10: 282. PMID: 33801386, PMCID: PMC7999794, DOI: 10.3390/pathogens10030282.Peer-Reviewed Original ResearchSerological responsePopulation-based cross-sectional surveyRecent malaria exposureMerozoite surface protein 8Non-exposed individualsCross-sectional surveyMalaria control effortsTime of surveyPV exposureMalaria exposureIgG antibodiesTransmission settingsPV infectionGood biomarkerRecent exposurePast monthIgGPlasma samplesProtein 8Second evaluationExposureFirst evaluationIndividualsLuminexCohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply